SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-161203
Filing Date
2024-06-14
Accepted
2024-06-14 08:30:31
Documents
14
Period of Report
2024-06-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d128195d8k.htm   iXBRL 8-K 33723
2 EX-10.1 d128195dex101.htm EX-10.1 265140
  Complete submission text file 0001193125-24-161203.txt   493091

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eigrq-20240613.xsd EX-101.SCH 2514
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigrq-20240613_lab.xml EX-101.LAB 17956
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigrq-20240613_pre.xml EX-101.PRE 11239
18 EXTRACTED XBRL INSTANCE DOCUMENT d128195d8k_htm.xml XML 3779
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 241043225
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)